Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Eric H Rubin"'
Autor:
Lei Xu, Razvan Cristescu, Jared Lunceford, Andrey Loboda, Andrew Albright, Xiao Qiao Liu, Alexandra Snyder, Fan Jin, Lixin Lang, Deepti Aurora-Garg, Eric H Rubin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/163044bed9ae453ba58ee9669cf74cb9
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis D. Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo H. Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1183-1190
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating,
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1175-1182
Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly in oncology. These data may include electronic health records, medical imaging, genomic sequencing, payor records, and data from pharmaceutica
Autor:
Lee S. Rosen, Simon Ashworth, Fang Fang, Y. Nancy Wong, Dale E. Shuster, Diana C. Walton, Eric H. Rubin, Antoinette R. Tan
Purpose: To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of eribulin mesylate (E7389), a halichondrin B analogue, administered every 21 days in patients with advanced solid tumors.Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84df5d1c98a1c5ea5b5ab2e556ba300a
https://doi.org/10.1158/1078-0432.c.6517653
https://doi.org/10.1158/1078-0432.c.6517653
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Supplementary material and tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38da5e6e6c6f6147a1c2587f817f6485
https://doi.org/10.1158/1078-0432.22474871.v1
https://doi.org/10.1158/1078-0432.22474871.v1
Autor:
Lee S. Rosen, Simon Ashworth, Fang Fang, Y. Nancy Wong, Dale E. Shuster, Diana C. Walton, Eric H. Rubin, Antoinette R. Tan
Editorial on this Article from Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f1ee5c26ebc43bfec7b5d78f00f53f3
https://doi.org/10.1158/1078-0432.22440303
https://doi.org/10.1158/1078-0432.22440303
Autor:
Keaven M. Anderson, Eric H. Rubin
Related Article from Finding the Right Dose for Cancer Therapeutics—Can We Do Better?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4eddedcfc5e7c1e3e5f5bdcfa4ae6d8
https://doi.org/10.1158/1078-0432.22442585.v1
https://doi.org/10.1158/1078-0432.22442585.v1
Autor:
Marian Iwamoto, John A. Wagner, Jeffery A. Chodakewitz, Wendy Comisar, Xiadong Li, Kristien Van Dyck, Jaclyn K. Patterson, Evan Friedman, Simon Van Belle, Eric H. Rubin, Pamela N. Munster
Supplementary Data from A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b5771cc329a7d4c48d3b6dcb05318bf
https://doi.org/10.1158/1078-0432.22440712
https://doi.org/10.1158/1078-0432.22440712
Autor:
Kathleen Moore, Eric H. Rubin, Shelonitda Rose, Jingjun Qiu, Ji Liu, Mark A. Lee, Tomoko Freshwater, Michael Tracy, Naomi Laing, Robert M. Wenham, Johanne I. Weberpals, Denise Uyar, Diane Provencher, Frederik Marmé, Marcia Hall, Eva-Maria Grischke, Maria Estevez-Diz, Amit M. Oza
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2904c5ffb104f34aa297ea68c6f981a0
https://doi.org/10.1158/1078-0432.22474877
https://doi.org/10.1158/1078-0432.22474877
Autor:
Johann S. de Bono, Li Yan, Timothy A. Yap, Brianne Kaiser, Victor Moreno, Kyriakos P. Papadopoulos, Ying-Ming Jou, Ernestina Tetteh, Anne Morosky, Keith A. Shannon, Maria Learoyd, Pearl Huang, Paul D. Smith, Eric H. Rubin, Jeffrey M. Skolnik, Christopher R. Garrett, David Olmos, Richard D. Baird, Amita Patnaik, David R. Gandara, Vassiliki Papadimitrakopoulou, Udai Banerji, Michael Ong, Khurum Khan, Anthony W. Tolcher
Supplementary Tables S1-S4 and Figures S1-S3. Tables S1/S2: % tumor response in mice with HCT116 and A2058 tumor xenografts following treatment; Table S3: Diagram showing dose-decision guidelines utilized in the MK-2206 clinical study based on observ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f597346417fd8a518a7f25a4fa93a7d
https://doi.org/10.1158/1078-0432.22458612
https://doi.org/10.1158/1078-0432.22458612